SCHEMBL798027

SCHEMBL798027

CC1CCN(Cc2ccc(C(C)(C)C)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.69
SIGMAR1 Q99720 3/20 0.68
ACHE P22303 3/20 0.64
TEAD1 P28347 2/20 0.54
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
DRD2 P14416 2/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
HTR2B P41595 1/20 0.51
KCNH2 Q12809 2/20 0.50
LMNA P02545 1/20 0.47
NR1I2 O75469 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CNR1 P21554 1/20 0.47
HRH1 P35367 1/20 0.47
OPRK1 P41145 1/20 0.47
PDE4D Q08499 1/20 0.47
GHSR Q92847 1/20 0.47
DRD4 P21917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL797735 0.90 SIGMAR1 (0.60) HRH3SIGMAR1ACHETEAD1MEN1
SCHEMBL17243556 0.87 HRH3 (0.65) HRH3SIGMAR1ACHETEAD1KCNH2
SCHEMBL12449549 0.86 TEAD1 (0.58) HRH3SIGMAR1TEAD1MEN1KMT2A
SCHEMBL1044315 0.85 KCNH2 (0.58) HRH3SIGMAR1TEAD1MEN1KMT2A
SCHEMBL14242820 0.85 HRH3 (0.67) HRH3SIGMAR1ACHETEAD1KCNH2
SCHEMBL12412709 0.85 ALDH1A1 (0.59) HRH3SIGMAR1ACHETEAD1MEN1
SCHEMBL9139565 0.85 TEAD1 (0.53) HRH3SIGMAR1ACHETEAD1MEN1
SCHEMBL13602641 0.85 TEAD1 (0.53) HRH3SIGMAR1TEAD1MEN1KMT2A
SCHEMBL24105582 0.83 HRH3 (0.69) HRH3SIGMAR1ACHELMNA
SCHEMBL798068 0.82 HRH3 (0.58) HRH3SIGMAR1TEAD1KCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
US-9216980-B2 Methods of use of diazacarbazoles for treating cancer GENENTECH, INC. (US) 2015-12-22 US disclosed
US-20150087630-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER GENENTECH, INC. (US) 2015-03-26 US disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20130261104-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER GENENTECH, INC. (US) 2013-10-03 US disclosed
US-8501765-B2 Diazacarbazoles and methods of use GENENTECH, INC. (US) 2013-08-06 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 HRH3 2165/4885SIGMAR1 1380/4885ACHE 1534/4885
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B HRH3 1289/4885SIGMAR1 4777/4885ACHE 4058/4885
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 HRH3 196/4885SIGMAR1 501/4885ACHE 3634/4885
US-20150087630-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER IDH3B, IDH3A, EGLN3 HRH3 690/4885SIGMAR1 1624/4885ACHE 1733/4885
US-20130261104-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER IDH3B, IDH3A, EGLN3 HRH3 690/4885SIGMAR1 1624/4885ACHE 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.